June 11 (Reuters) - Achieve Life Sciences Inc ACHV.O :
* ACHIEVE LIFE SCIENCES ANNOUNCES STATISTICALLY SIGNIFICANT IMPROVEMENT IN QUIT RATES FOR SIMPLIFIED CYTISINICLINE DOSING SCHEDULE IN PHASE 2B ORCA-1 DOSE-SELECTION TRIAL
* ACHIEVE LIFE SCIENCES INC - CYTISINICLINE WAS WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS REPORTED
* ACHIEVE LIFE SCIENCES INC - THREE OF FOUR CYTISINICLINE TREATMENT ARMS DEMONSTRATED A STATISTICALLY SIGNIFICANT IMPROVEMENT
* ACHIEVE LIFE SCIENCES INC - EXPECTS TO CONDUCT FURTHER ANALYSES OF ORCA-1 TRIAL AND SUBMIT DATA FOR PRESENTATION AT A FUTURE MEDICAL MEETING
* ACHIEVE LIFE SCIENCES INC - ALL FOUR CYTISINICLINE ARMS DEMONSTRATED STATISTICALLY SIGNIFICANT (P < 0.05) REDUCTIONS IN EXPIRED CO
* ACHIEVE LIFE SCIENCES INC - PLANS TO DISCUSS TRIAL'S OUTCOME WITH FDA AND FINALIZE PHASE 3 PROTOCOL DETAILS IN SECOND-HALF OF 2019
* ACHIEVE LIFE SCIENCES INC - 3.0 MG, 3 TIMES DAILY SELECTED AS DOSE FOR FUTURE CLINICAL DEVELOPMENT
* ACHIEVE LIFE SCIENCES INC - FOURTH CYTISINICLINE TREATMENT ARM TRENDED TO SIGNIFICANCE (P= 0.052)